Streamlining Dermatology Biologics Prior Auth

Efficiently manage dermatology biologics prior auth with Klivira's intelligent automation platform, designed to reduce administrative burden and accelerate patient access to critical therapies.

Dermatology practices face significant administrative challenges in securing prior authorizations for high-cost biologics and complex procedures. The intricate requirements for specialty drugs, coupled with the need for periodic re-authorizations, can strain revenue cycle operations and delay essential patient care.

The Unique Landscape of Dermatology Biologics Prior Authorization

Dermatology prior authorization is heavily concentrated around biologics for chronic conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa, alongside high-volume procedures such as Mohs micrographic surgery. These treatments often involve complex step therapy protocols, specific diagnostic criteria, and ongoing re-authorization cycles, making manual processes resource-intensive.

High-Volume PA Categories in Dermatology

Biologics for psoriasis and psoriatic arthritis (e.g., adalimumab/Humira, secukinumab/Cosentyx, guselkumab/Tremfya, risankizumab/Skyrizi).
Biologics for atopic dermatitis (e.g., dupilumab/Dupixent, tralokinumab/Adbry).
Biologics for hidradenitis suppurativa (e.g., adalimumab/Humira).
Mohs micrographic surgery for non-melanoma skin cancers in cosmetically sensitive areas.
Advanced skin cancer treatments, including immunotherapies and targeted therapies.
Select phototherapy regimens, particularly for home administration.

Navigating Clinical Guidelines and Documentation Requirements

Payer policies for dermatology biologics and procedures are rigorously aligned with clinical guidelines from organizations like the American Academy of Dermatology (AAD) and the National Comprehensive Cancer Network (NCCN). Successful prior authorization hinges on meticulous documentation of disease severity (e.g., PASI, BSA, EASI, SCORAD), trial of prior therapies (topicals, phototherapy, conventional systemics), and pre-biologic screenings (TB, hepatitis).

Frequent Challenges in Dermatology PA Submissions

Failure to document completion of required step therapy for psoriasis biologics (e.g., prior topical, phototherapy, or methotrexate trials).
Lack of documented disease severity scores (PASI, EASI, BSA) crucial for meeting payer criteria.
Mismatch with Mohs Appropriate Use Criteria (AUC) regarding tumor type or anatomical site.
Incomplete pre-biologic screening results for tuberculosis or hepatitis.
Payer mandates for biosimilar substitution not addressed.

Klivira's Intelligent Automation for Dermatology Biologics Prior Auth

Klivira provides a purpose-built solution for dermatology practices, integrating directly with EMRs to automate the complex prior authorization workflow for biologics and high-volume procedures. Our platform streamlines the extraction of clinical data, applies AAD-guideline-aware step-therapy logic, and facilitates rapid submission through appropriate payer channels, including X12 278 and payer portals.

Klivira Platform Capabilities for Dermatology

Automated extraction of clinical documentation from EMRs (e.g., diagnoses, lab results for TB/hepatitis screening, prior therapy history), often leveraging FHIR-based integrations.
Intelligent application of step-therapy rules and biosimilar substitution policies for biologics like Dupixent, Cosentyx, and Humira.
Validation against Mohs Appropriate Use Criteria (AUC) to mitigate denials.
Proactive management of periodic re-authorization cycles for chronic biologic treatments.
Dynamic routing for medical-vs-pharmacy benefit based on administration mode (self-injection vs. clinic infusion).
Direct connectivity to payer portals and X12 278 for efficient submission and status tracking.

Frequently asked questions

How does Klivira handle the specific step-therapy requirements for psoriasis biologics?

Klivira's platform incorporates AAD-guideline-aware step-therapy logic. It automatically identifies and verifies documentation of prior topical therapies, phototherapy trials, or conventional systemic agents like methotrexate from EMR data, ensuring compliance with payer protocols before submission.

Can Klivira assist with prior authorizations for Mohs micrographic surgery?

Yes, Klivira validates Mohs surgery requests against Appropriate Use Criteria (AUC) by extracting relevant details such as tumor type, size, and anatomical site from the EMR. This helps ensure submissions align with payer policies, reducing the likelihood of denials.

How does Klivira manage periodic re-authorization for chronic biologic treatments?

Klivira's workflow includes proactive alerts and automated processes for periodic re-authorization, typically on 6 or 12-month cycles. The system helps compile necessary documentation on ongoing disease activity and treatment response, ensuring timely renewals without interruption to patient care.

What EMR data does Klivira utilize for dermatology biologics prior auth?

Klivira extracts critical clinical data from your EMR, including diagnoses, disease severity scores (PASI, EASI, BSA), medication history (prior topical/systemic therapies), and lab results for pre-biologic screenings (TB, hepatitis), often leveraging FHIR-based integrations.

Does Klivira differentiate between medical and pharmacy benefit for biologics?

Yes, Klivira's platform is designed to dynamically route prior authorization requests based on whether a biologic is administered via self-injection (often pharmacy benefit) or clinic infusion (often medical benefit). This ensures correct submission to the appropriate payer channel.